Inhalation anesthesia is a chemical compound, also termed as volatile anesthetic agents. It has an ability of induction and maintenance of general anesthesia & sedation. It is delivered through inhalation, especially in patients where management of anesthetics through intravenous route and other routes is not feasible. It causes decrease in arterial blood pressure, respiratory depression, and cerebral metabolic demand along with rise in cerebral blood flow.
According to study, “Global inhalation anesthesia market Size study, by product (sevoflurane, desflurane and isoflurane) Application (induction and maintenance) and Regional Forecasts 2018-2025” the key companies operating in the global inhalation anesthesia market are Halocarbon Products Corporation, Halocarbon Products Corporation, AbbVie, Inc., Lunan Pharmaceuticals Co Ltd., Baxter, Jiangsu Hengrui Medicine Co. Ltd., Piramal Healthcare, Fresenius Kabi AG.
Based on product type, inhalation anesthesia market is segmented into isoflurane, desflurane, sevoflurance and others. Isoflurane segment is anticipated to witness the fastest CAGR owing to rise in use in maintenance of anesthesia for treatment of weak or geriatric patients due to its sparing effect on cardiovascular function during the forecast period. Additionally, Sevoflurane segment holds major share in market as a result of its therapeutic advantages such as low cost and higher potency for an induction of anesthesia. Based on application, market is segmented into induction and maintenance. Maintenance segment also holds major share in market as a result of rise in requirement of higher volumes for maintenance of inhalation anesthetics. In addition, based on end-user, market is segmented into ambulatory surgical centers, hospitals & clinics and others. Ambulatory surgical centers dominate the market because of reduced risk of hospital acquired infections, excellence treatment at affordable prices and shorter hospital stay. Hospital segment is expected to exhibit higher CAGR caused by growth in demand for various surgical procedures on account of favorable reimbursement policies for surgeries being performed in hospital settings during the forecast period.
The inhalation anesthesia market is driven by rise in demand for lesser duration in hospitalization, followed by increase in geriatric population prone to chronic diseases, growth in patient inclination towards ambulatory day care procedures, unhealthy dietary habits & lifestyle changes, rise in availability of healthcare insurance for masses, increase in number of orthopedic procedures for instance ligament and other soft tissue repair procedures, growth in accessibility to health services & surgeries and rise in number of emergency cases. However, recent patent expiries, generic competition for almost all of the halogenated agents and side effects of inhaler anesthesia drugs may impact the market. Moreover, growth in innovation in field of inhalation anesthetics and constant improvements in the healthcare set-up are key opportunities for market.
Based on geography, the North-American region dominates the inhalation anesthesia market owing to rise in prevalence of chronic disease, increase in sound healthcare infrastructure, rise in public & private healthcare expenditure, growth in number of cosmetic procedures (Surgical and non-surgical) in the region. The Asian-Pacific region is estimated to witness higher growth rate due to rise in geriatric population, growth in medical tourism and increase in number of hospitals & clinics over the forecast period. In upcoming years, it is predictable that future of the market will be optimistic on account of rise in benefits of inhalation anesthetics over injectable anesthetics during the forecast period. It is projected that the market will be reached at US $1.4 billion by 2025.
For more information on the research report, refer to below link:-
Ankur Gupta, Head Marketing & Communications